Thomas Gad is Chairman, Founder, President, and Head of Business Development and Strategy. Inspired by his daughter’s transformational and challenging journey through years of high-risk neuroblastoma treatment and her experience receiving breakthrough immunotherapy at Memorial Sloan Kettering Cancer Center to overcome the cancer, Mr. Gad founded Y-mAbs Therapeutics, securing executive management and seed capital for the inception of the Company. Mr. Gad has more than 12 years of experience in the pharmaceutical industry, including business development, senior management, financing, and licensing negotiations. Mr. Gad has a Bachelor of Science degree in Business Administration from Pepperdine University, California, US.
Claus Moller, MD, PhD, serves as Chief Executive Officer of the Company. Dr. Moller is the Founder of Azanta A/S and was the Chief Executive Officer of Azanta from 2009 to 2015. In addition, Dr. Moller has extensive experience in the pharmaceutical and biotechnology industries and was a co-founder of one of the largest European biotech companies, Genmab A/S, in 1999, where he served as Executive Vice President and Chief Operating Officer until 2008. Previous positions include Executive Vice President and Chief Medical and Operating Officer of OXiGENE, Inc., and Medical Director of Synthélabo Scandinavia. Dr. Moller received his MD and PhD degrees from the University of Copenhagen, Denmark.
Bo Kruse serves as Chief Financial Officer, Treasurer, and Secretary of the Company. Mr. Kruse has broad international finance experience, including knowledge of capital markets, accounting, and other financing activities. Prior to joining the Company, Mr. Kruse was the Chief Financial Officer of the Danish biotech company Azanta A/S from 2009 to 2015. Further, Mr. Kruse served as Genmab A/S’ Vice President and Chief Financial Officer from 2005 to 2008, and in a number of other finance positions, including Vice President and Chief Accounting Officer, from 2000 to 2005. During his eight-year tenure at Genmab, Mr. Kruse was directly involved in several financing rounds, including Genmab’s initial public offering. Mr. Kruse has a Master’s and Bachelor of Science in Commerce degree from Copenhagen Business School, Denmark.
Torben Lund-Hansen, PhD, serves as SVP, Head of Technical Operations. Dr. Lund-Hansen has substantial experience in antibody process development, commercial manufacturing, and global project management from his time at Novo Nordisk A/S, Maxigen, Inc., and Genmab A/S. At Genmab, he served as Senior Vice President, Technical Operations, and was responsible for outsourcing clinical and commercial drug substance and drug product manufacturing. From 2008 to 2009, he was President and Treasurer for Genmab Mn, Inc., in Minnesota, US. Dr. Lund-Hansen has been responsible for compiling technical CMC documentation packages submitted to global regulatory agencies, followed by approval and launch of several biologics. Dr. Lund-Hansen received his MSc and PhD from the University of Copenhagen, Denmark.
Steen Lisby, MD, DMSc, serves as SVP, Chief Medical Officer. Dr. Lisby received his MD and his Doctorate of Medical Science from the University of Copenhagen, Denmark, and has extensive clinical and scientific experience. He is the author of over 50 scientific, peer-reviewed publications in the field of clinical research. Dr. Lisby previously worked at GlaxoSmithKline plc and Genmab A/S. In 2015, he was appointed VP, Head of Medical, at Genmab, and subsequently ended his tenure with Genmab in June 2017.
Joris Wilms serves as SVP, Chief Operating Officer. Mr. Wilms has extensive industry experience in clinical development, with a focus in oncology and hematology indications. He has been responsible for overseeing several first-in-human studies and pivotal clinical trials, leading to the approval of two monoclonal antibodies. Previous positions include VP, Clinical Trial Services and Pharmacovigilance, at KLIFO A/S, and Associate Director, Clinical Development, at Genmab A/S. Mr. Wilms received his MSc Pharm from the University of Groningen, Netherlands.
Mahiuddin Ahmed, PhD, serves as SVP, Chief Scientific Officer. Dr. Ahmed is an expert in antibody and therapeutic protein engineering based on in silico design. He received his PhD in Biochemistry and Structural Biology from Stony Brook University and completed postdoctoral training in cancer immunotherapy at the Sloan Kettering Institute. He was formerly a faculty member in the Department of Pediatrics at Memorial Sloan Kettering and is an inventor of numerous issued and pending patents related to therapeutic proteins, bispecific antibodies, radioimmunotherapy products and related technologies. Dr. Ahmed oversees the Y-mAbs R&D Laboratories in Nutley, NJ.
Philip Herman serves as SVP, Chief Commercial Officer. Mr. Herman brings extensive commercial experience with a focus in oncology and rare diseases. He has a proven track record of commercial success, including launch and sales attainment across the full product life cycle. Previous positions include VP, Head of Santhera U.S. and Head of Commercial, Head of Marketing at Dyax Corp., Director of Marketing at Vanda Pharmaceuticals, and various commercial positions of increasing responsibility at Pfizer. Mr. Herman received his MBA from the Kellogg School of Management at Northwestern University.